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 EditoriAL
drug transporters are integral membrane proteins expressed by a variety of organs, including the liver, kidney, small 
intestine and testis, and they are generally known to mediate drug or xenobiotic transport into and out of cells. Previous 
studies have also reported the presence of several drug transporters at blood-tissue barriers where they are thought 
to protect organs from harmful agents. in this editorial, we briefly discuss and re-evaluate recent findings that show 
P-glycoprotein, an efflux pump, to function at the blood-testis barrier. We also put forth a mechanistic model, hoping this 
information will form a strong basis for future studies.
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Multidrug resistance (MDR) occurs when a disease-causing 
organism (i.e., bacteria, fungi or parasite) or a disease-causing 
cell (i.e., neoplastic or virally-infected) does not respond to a 
pharmacological agent(s) that is designed to destroy it. One of 
the most well-known examples of MDR to make headlines in 
recent years relates to methicillin-resistant Staphyolococcus aureus 
(MRSA), the so-called ‘super bug’ residing in many hospitals and 
nursing homes that is almost impossible to eradicate by trusted 
and widely prescribed antibiotics such as methicillin, amoxicillin 
and penicillin. MDR can also manifest itself in neoplastic cells, 
as well as in immune cells harboring, for example, the human 
immunodeficiency virus (HIV). In all cases, MDR is a condition 
that prevents a drug(s) from reaching or accumulating its thera-
peutic dose and results in drug insensitivity so that individuals 
presenting for MDR remain ‘clinically untreated’, and this can 
result in death. Because MDR limits treatment options for those 
with life-debilitating and life-threatening conditions, it is a major 
concern that continues to elude physicians and healthcare profes-
sionals, as well as researchers trying to find an effective way to 
reverse it.
It is not completely understood why the MDR phenotype is 
triggered in some individuals and not in others. While MDR is 
known to associate with several mechanisms, perhaps the most 
well studied involves drug transporters (i.e., increased expression 
of efflux pumps and/or decreased expression of influx pumps). 
Drug transporters are integral membrane proteins that pump 
drugs and xenobiotics, as well as endogenous compounds such 
as steroids, into or out of cells, and two superfamilies have been 
identified in mammals: the ATP-binding cassette (ABC) super-
family of efflux transporters (P-glycoprotein or MDR1 is the 
best-studied efflux pump) and the solute carrier (SLC) super-
family of influx transporters.1-4 Interestingly, drug transporters 
are not only expressed by disease-causing organisms and cells;5-10 
normal cells such as hepatocytes, epithelial cells in the intestine, 
Sertoli and germ cells in the testis are also known to express drug 
transporters. In fact, many drug transporters are known to be 
present at blood-tissue barriers where they are presumed to pro-
tect sensitive organs from dangerous exogenous agents.11-15 For 
example, knockout of Mdr1a (in rodents, MDR1 is encoded by 
Mdr1a and Mdr1b), which was previously shown to localize at 
the blood-brain (BBB) and the blood-testis barrier (BTB), ren-
dered mice more susceptible to the harmful effects of ivermectin 
(an antiparasitic drug) and vinblastine (an anticancer drug).16 
Specifically, increased uptake of these compounds was observed 
in the brain and in the testis of Mdr1a−/− vs. wt mice, illustrating 
that P-glycoprotein safeguards these organs by pumping out or 
prohibiting entry of harmful substances.
Recent studies from our group, as well as those from other lab-
oratories, have shown testicular cells to express an array of drug 
transporters. For example, P-glycoprotein localized to Sertoli 
cells, late spermatids, Leydig cells and peritubular myoid cells.17,18 
Within Sertoli cells, P-glycoprotein, as well as another drug 
transporter [i.e., organic anion transporter protein 3 (OATP3)], 
concentrated to the site of the BTB, and P-glycoprotein co-
immunoprecipitated with structural tight junction (TJ) proteins, 
namely occludin, claudin-11 and junctional adhesion molecule-A © 2012 Landes Bioscience.
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(JAM-A), when normal testis and/or Sertoli cell lysates were 
used.18-20 Equally important, knockdown of Mdr1a + Mdr1b 
(referred to as Mdr1 from here onwards) in rat Sertoli cells by 
RNA interference (RNAi) was found to partially compromise the 
integrity of the Sertoli cell barrier when its function was assessed 
by transepithelial electrical resistance measurements, as well as 
by immunoblotting and immunolocalization experiments.19 
Interestingly, destabilization of the Sertoli cell barrier following 
Mdr1 RNAi appeared to involve multiple mechanisms that may 
or may not be inter-related (Fig. 1). Following Mdr1 silencing, 
occludin was found to dissociate from zonula occludens-1 (ZO-1) 
and to associate increasingly with focal adhesion kinase (FAK), 
which brought about changes in occludin phosphorylation 
(i.e., a decrease and an increase in overall Ser and Thr phos-
phorylation, respectively, with no changes in overall Tyr phos-
phorylation).19 However, the significance of these results is not 
immediately known because in general hyper-phosphorylation 
of Ser-/Thr-occludin associates with TJ stability, whereas 
hyper-phosphorylation of Tyr-occludin associates with TJ dys-
function.21,22 These changes may be related to the uniqueness of 
the BTB, and future experiments employing site-specific phos-
pho antibodies against occludin are likely to be more informative. 
Nevertheless, these results still fall in line with those obtained 
from endocytosis assays, which demonstrated an increase in 
occludin internalization over control levels19 (Fig. 1). Another 
mechanism relates to the decline (albeit moderate) in the steady-
state level of claudin-11 that was noted following Mdr1 RNAi, 
but at this point we cannot conclude if this decrease in claudin-11 
was the result of increased protein degradation or decreased pro-
tein synthesis. Certainly, mislocalization of occludin may have 
provoked the mislocalization of claudin-11 away from the plasma 
membrane, contributed to its instability and triggered its deg-
radation. Other mechanisms are likely to be at play as well. For 
instance, Mdr1 silencing may have allowed entry of unknown 
compounds past the BTB and into the adluminal compartment 
of Sertoli cells, which would have otherwise been prohibited from 
Figure 1. A mechanistic model of P-glycoprotein function at the BtB. Previous studies have shown P-glycoprotein to localize at the BtB and to co-
immunoprecipitate with structural tJ proteins, namely occludin, claudin-11 and JAM-A, which assemble into a multi-protein complex via Zo-1 and 
FAK (see text for references). to better understand the role of P-glycoprotein at the BtB, sertoli cells were isolated from testes of 20-d-old rats and 
cultured at high density on Matrigel-coated substrata for 3–4 d to allow the assembly of a functional sertoli cell barrier. thereafter, Mdr1 was silenced 
by rnAi (denoted by an “X”), and barrier function was assessed by transepithelial electrical resistance measurements, immunoblotting and immuno-
localization experiments. Following knockdown, sertoli cell barrier dysfunction was noted. specifically, the association between occludin and Zo-1 
was disrupted (denoted by connected lines that end with an “X”), which increased the association between occludin and FAK. this resulted in the thr 
phosphorylation (denoted by an encircled “P”) and in the endocytosis (denoted by a large circle) of occludin, disrupting the integrity of tJs. A decrease 
in the steady-state level of claudin-11 (denoted by a dotted-line and by connected lines that end with an “X”) was also observed following knockdown, 
contributing to tJ dysfunction as well. BtB dysfunction resulting from the loss of P-glycoprotein may have also allowed entry of drugs, toxicants and 
steroids (denoted by an assortment of symbols), which would have otherwise been prohibited from entering the adluminal compartment of the 
seminiferous epithelium or pumped out in the presence of P-glycoprotein at the BtB. An additional study has reported P-glycoprotein to associate 
with actin via the ezrin-radixin and moesin (ErM) protein complex,28 but it is not known if this finding applies to the testis as well. Future experiments 
are also needed to identify the mechanism behind the decrease in claudin-11 following knockdown of Mdr1. For simplicity, other junction types that 
contribute to BtB function have been omitted, and only selected tJ proteins have been included.© 2012 Landes Bioscience.
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entering or pumped out in the presence of P-glycoprotein at the 
BTB. This may have also affected BTB function (Fig. 1). At this 
point, additional studies are needed to better understand the role 
of P-glycoprotein and other drug transporters at the BTB.
What might some of these studies be? First, would a disrup-
tion (or at least a partial disruption) of the Sertoli cell barrier/
BTB affect P-glycoprotein-mediated drug efflux? For instance, 
would knockdown of a critical TJ protein such as claudin-11, 
which is known to bind P-glycoprotein, increase the influx 
of P-glycoprotein substrates? If yes, one could conclude that 
BTB integrity is essential for P-glycoprotein function. Second, 
is aberrant regulation of drug transporters (efflux and influx 
pumps alike) linked to unexplained cases of male infertility? 
Environmental toxicants can utilize drug transporters expressed 
by the testis. The best example of this is the entry of cadmium by 
SLC39A8, a xenobiotic transporter and influx pump.23,24 Thus, 
targeted manipulation of drug transporter expression may pro-
tect the testis from harmful substances and preserve fertility. 
This may also be applicable to men receiving chemotherapy, 
which in many cases is known to jeopardize their ability to 
father children. Finally, internalization of P-glycoprotein has also 
been reported, and when this occurs, P-glycoprotein function is 
compromised.25-27 In-depth investigations along these fronts are 
likely to yield interesting observations, not only with respect to 
P-glycoprotein function but also with respect to BTB dynamics 
which are critical for spermatogenesis.
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